سعر جنتاميسين اليكس 80 مجم / 2 مل 3 امبولات 2024

Gentamicin sulfate solution for intramuscular/intravenous injection (80 mg/2 ml), 3 ampoules × 2 ml, manufactured/marketed in Egypt by Alexandria.

• Treatment of serious infections caused by susceptible strains of Pseudomonas aeruginosa, Proteus spp., E. coli, Klebsiella-Enterobacter-Serratia spp., Citrobacter spp., and Staphylococcus spp., including bacterial septicemia, neonatal sepsis, and serious infections of the CNS (meningitis), urinary tract, respiratory tract, GI tract (including peritonitis), skin, bone and soft tissue (including burns).Population: Adults and pediatric patients as labeledDailyMed / FDA

• Nephrotoxicity (casts, cells or protein in urine; rising BUN/creatinine; oliguria) and neurotoxicity affecting vestibular and auditory eighth-nerve function (dizziness, vertigo, tinnitus, hearing loss) are the principal adverse effects; other reported effects include rash, nausea, injection-site pain, and electrolyte disturbances.International label, equivalent formulation · DailyMed / FDA

• Hypersensitivity to gentamicin is a contraindication. A history of hypersensitivity or serious toxic reactions to other aminoglycosides may contraindicate use because of known cross-sensitivity.International label, equivalent formulation · DailyMed / FDA

• Aminoglycosides are potentially nephrotoxic and ototoxic (vestibular and auditory; usually irreversible). Closely monitor renal and eighth cranial nerve function; adjust or discontinue for toxicity. Avoid prolonged peak serum levels above 12 mcg/mL and trough levels above 2 mcg/mL when monitoring.International label, equivalent formulation · DailyMed / FDA
• Aminoglycosides can cause fetal harm when administered to a pregnant woman; apprise patient of potential hazard to the fetus if used in pregnancy.International label, equivalent formulation · DailyMed / FDA
• Cases of ototoxicity have been observed in patients with certain mitochondrial DNA variants (MT-RNR1, particularly m.1555A>G), even with serum levels within the recommended range; consider alternatives unless benefits outweigh risk of permanent hearing loss.International label, equivalent formulation · DailyMed / FDA

• Other nephrotoxic/neurotoxic drugs (e.g. cisplatin, amikacin, tobramycin, vancomycin, polymyxins) and potent diuretics (ethacrynic acid, furosemide)MajorConcurrent and/or sequential use of other potentially neurotoxic or nephrotoxic drugs should be avoided. Concurrent use with potent diuretics should be avoided because diuretics themselves may cause ototoxicity and may alter antibiotic serum/tissue concentrations.DailyMed / FDA
• Neuromuscular blocking agents / anestheticsMajorNeuromuscular blockade and respiratory paralysis may occur if aminoglycosides are given with anesthetics or neuromuscular blockers; calcium salts may reverse blockade.DailyMed / FDA

• Aminoglycosides can cause fetal harm; there have been reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy. Animal studies with gentamicin did not reveal impaired fertility or fetal harm in rats/rabbits, but human data for gentamicin are limited. If used in pregnancy, apprise the patient of potential hazard to the fetus.International label, equivalent formulation · DailyMed / FDA

• Gentamicin: Bactericidal; its most important effect is inhibition of bacterial protein synthesis at the level of the 30S ribosomal subunit; also affects plasma-membrane integrity and RNA metabolism (UK SmPC, gentamicin eye/ear drops).